Tin tức & Cập nhật

‘Inclisiran first’ strategy in ASCVD reduces LDL-C

Among patients with atherosclerotic cardiovascular disease (ASCVD) who fail to achieve guideline-directed low-density lipoprotein cholesterol (LDL-C) goals despite receiving maximally tolerated statins, initiating inclisiran immediately resulted in significant reductions in LDL-C, according to the VICTORION-INITIATE trial presented at ACC.24.

Web-based app to guide nonprescription use of statins a win in TACTiC trial

Self-selecting for nonprescription statin therapy with the help of a Web-based application leads to a high percentage of individuals correctly confirming their eligibility, using the medication appropriately, and achieving significant low-density lipoprotein cholesterol (LDL-C) reductions, according to the results of the TACTiC trial.

Secukinumab, adalimumab biosimilar compare favourably for treating axial spondyloarthritis

In the treatment of radiographic axial spondyloarthritis (r-axSpA), the 2-year incidence of spinal radiographic progression is low and not different between secukinumab and adalimumab biosimilar, as shown in the phase IIIb study SURPASS study.

Investigational agent works well for migraine in pooled analysis

Treatment with the investigational agent AXS-07 significantly alleviates pain and most bothersome symptoms (MBS) in patients with migraine, according to results of a pooled analysis of the phase III MOMENTUM and INTERCEPT trials presented at AAN 2024.

SGLT2 inhibitors a promising gout medication in T2D

The use of sodium-glucose cotransporter type 2 (SGLT2) inhibitors lowers the risk of incident gout or recurrent gout flares among patients with type 2 diabetes who are taking metformin, as shown in a study.

Erenumab helps with rosacea-associated flushing, erythema

Monthly subcutaneous injections of the anti–CGRP-receptor monoclonal antibody erenumab appear to be beneficial in the management of flushing and chronic redness among individuals with rosacea, according to a study.

[Infographic] Hướng dẫn sử dụng thuốc nhỏ mũi đúng cách

Tirbanibulin 1% ointment for actinic keratoses passes muster in real world

Tirbanibulin 1% ointment proves safe and effective in patients with multiple actinic keratoses (AKs) treated in real-world settings, as shown in a study.

Do GLP1 receptor agonists increase thyroid cancer risk?

Use of glucagon-like peptide 1 (GLP1) receptor agonists does not contribute to an elevated risk of thyroid cancer, as shown in a Scandinavian cohort study with a mean follow-up of nearly 4 years.